Lupin Ltd Shares Rise to 52-Week High Amid Regulatory Approvals

Lupin Ltd's share price rose over 1.6% to Rs 2,286.5, hitting a 52-week high of Rs 2,299.70 during intraday trade, outperforming the Nifty and Nifty Pharma indices. The stock has gained around 7% in the past month and 9% in 2026, compared to broader market gains and declines. Lupin recently received USFDA approval for Brivaracetam Oral Solution and European Commission approval for its biosimilar Ranluspec, expanding its pharmaceutical portfolio in key markets.